AQR Capital Management LLC Lowers Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AQR Capital Management LLC lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 395,771 shares of the medical equipment provider's stock after selling 58,583 shares during the period. AQR Capital Management LLC owned 0.57% of Lantheus worth $31,776,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Alpha DNA Investment Management LLC purchased a new position in Lantheus during the second quarter valued at $412,000. Point72 Europe London LLP bought a new position in Lantheus during the second quarter valued at approximately $6,198,000. Point72 Hong Kong Ltd purchased a new position in Lantheus during the 2nd quarter valued at approximately $764,000. Point72 Asset Management L.P. bought a new stake in Lantheus in the 2nd quarter worth approximately $26,794,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Activity at Lantheus

In other news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,852 shares of company stock valued at $3,922,001. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Performance

Lantheus stock traded up $2.39 during midday trading on Monday, hitting $109.75. 609,634 shares of the company were exchanged, compared to its average volume of 1,010,075. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The business has a fifty day simple moving average of $104.36 and a two-hundred day simple moving average of $86.40. The firm has a market capitalization of $7.61 billion, a PE ratio of 16.76 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same period in the prior year, the business posted $1.40 EPS. Lantheus's revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target on the stock. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Truist Financial lowered their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Finally, Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.